tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ANRO Stock Latest News

Alto Neuroscience initiated with a Buy at BTIG
The FlyAlto Neuroscience initiated with a Buy at BTIG
5d ago
ANRO
Alto Neuroscience, Inc.: Promising Future with Strategic Advancements and Strong Financial Position
PremiumRatings
Alto Neuroscience, Inc.: Promising Future with Strategic Advancements and Strong Financial Position
8d ago
ANRO
Promising Future for Alto Neuroscience: Buy Rating Backed by Strong Financials and Innovative Treatment Prospects
PremiumRatings
Promising Future for Alto Neuroscience: Buy Rating Backed by Strong Financials and Innovative Treatment Prospects
9d ago
ANRO
Alto Neuroscience price target raised to $22 from $16 at Baird
PremiumThe Fly
Alto Neuroscience price target raised to $22 from $16 at Baird
9d ago
ANRO
Promising Future for Alto Neuroscience: Buy Rating Backed by Strong Financials and Clinical Advancements
PremiumRatings
Promising Future for Alto Neuroscience: Buy Rating Backed by Strong Financials and Clinical Advancements
9d ago
ANRO
Alto Neuroscience’s ALTO-207: A Promising Candidate for Treatment-Resistant Depression with Significant Financial Projections
PremiumRatingsAlto Neuroscience’s ALTO-207: A Promising Candidate for Treatment-Resistant Depression with Significant Financial Projections
10d ago
ANRO
Alto Neuroscience price target raised to $25 from $15 at Jefferies
Premium
The Fly
Alto Neuroscience price target raised to $25 from $15 at Jefferies
10d ago
ANRO
Buy Recommendation for Alto Neuroscience Driven by Promising ALTO-207 Acquisition and Strategic Financial Backing
Premium
Ratings
Buy Recommendation for Alto Neuroscience Driven by Promising ALTO-207 Acquisition and Strategic Financial Backing
23d ago
ANRO
Alto Neuroscience’s ALTO-101 Study: A Potential Game-Changer for Schizophrenia Treatment?
PremiumCompany Announcements
Alto Neuroscience’s ALTO-101 Study: A Potential Game-Changer for Schizophrenia Treatment?
25d ago
ANRO
Alto Neuroscience’s ALTO-300 Study: A Potential Game-Changer in Depression Treatment
PremiumCompany Announcements
Alto Neuroscience’s ALTO-300 Study: A Potential Game-Changer in Depression Treatment
26d ago
ANRO
Alto Neuroscience’s ALTO-100 Study: A Potential Game-Changer for Bipolar Disorder Treatment?
PremiumCompany Announcements
Alto Neuroscience’s ALTO-100 Study: A Potential Game-Changer for Bipolar Disorder Treatment?
26d ago
ANRO
Alto Neuroscience’s Strategic Advancements and Regulatory Milestones Justify Buy Rating
PremiumRatings
Alto Neuroscience’s Strategic Advancements and Regulatory Milestones Justify Buy Rating
29d ago
ANRO
Alto Neuroscience price target raised to $50 from $10 at H.C. Wainwright
PremiumThe FlyAlto Neuroscience price target raised to $50 from $10 at H.C. Wainwright
29d ago
ANRO
Alto Neuroscience price target raised to $16 from $10 at Baird
Premium
The Fly
Alto Neuroscience price target raised to $16 from $10 at Baird
1M ago
ANRO
Alto Neuroscience Secures $50M in Private Placement
Premium
Company Announcements
Alto Neuroscience Secures $50M in Private Placement
1M ago
8K
ANRO
Alto Neuroscience, Inc.: Accelerated Drug Development and Strong Clinical Trial Compliance Drive Buy Rating
PremiumRatings
Alto Neuroscience, Inc.: Accelerated Drug Development and Strong Clinical Trial Compliance Drive Buy Rating
1M ago
ANRO
Midday Fly By: AWS hit by outage, Kering sells beauty unit
PremiumThe Fly
Midday Fly By: AWS hit by outage, Kering sells beauty unit
1M ago
BA
DX
Alto Neuroscience, Inc.: Strategic Advancements and Financial Strength Drive Buy Rating
PremiumRatings
Alto Neuroscience, Inc.: Strategic Advancements and Financial Strength Drive Buy Rating
1M ago
ANRO
Alto Neuroscience price target raised to $16 from $10 at Baird
PremiumThe Fly
Alto Neuroscience price target raised to $16 from $10 at Baird
1M ago
ANRO
Alto Neuroscience to sell 3.832M shares at $5.91 in private placement
PremiumThe FlyAlto Neuroscience to sell 3.832M shares at $5.91 in private placement
1M ago
ANRO
Alto Neuroscience plans to accelerate development of ALTO-207
Premium
The Fly
Alto Neuroscience plans to accelerate development of ALTO-207
1M ago
ANRO
Optimistic Buy Rating for Alto Neuroscience, Inc. Amidst Promising Developments and FDA Fast Track Designation
Premium
Ratings
Optimistic Buy Rating for Alto Neuroscience, Inc. Amidst Promising Developments and FDA Fast Track Designation
2M ago
ANRO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >